Xenocor

Creators of the Revolutionary Xenoscope

Xenoscope

Product Overview

Xenoscope 5mm and 10mm disposable HD Laparoscopes

The Xenocor fog proof laparoscope was created to provide safe and superior HD imagery for hospitals, surgery centers and medical outreach organizations. It solves the clinical challenges encountered during laparoscopy and is beneficial to supply chain initiatives. The Xenoscope system is FDA cleared for the 5mm and 10mm scopes and CE Marked for the 10mm scope.

Xenobox HD Image Processing Adaptor

The Xenobox is all that is needed to utilize the Xenoscope with your current imaging platform. It functions as a universal adapter for any video system as well as the power supply for the integrated light source and HD camera.

Xenobox HD Image Processing Adaptor

The Xenobox is all that is needed to utilize the Xenoscope with your current imaging platform. It functions as a universal adapter for any video system as well as the power supply for the integrated light source and HD camera.

XENOSCOPE

Product Advantages

Request Demo



Easy To Use

Lightweight
Compatible with all HD Monitors, TV’s, Tablets and existing O.R. imaging infustructure.
No capital expenditure or service contracts.
No cleaning, inspecting or re-processing.
Ready for use right off the shelf



Consistent HD Visualization

Designed to provide HD 1080P image with Clearview Technology (TM)
Integrated light source and digital HD camera utilizing plug and play technology.
Fog proof
Consistent image through electrocautery smoke
Manual focus to improve workflow



Safe

Non-conducting shaft removes the risk of electrosurgical arcing.
Low temperature Illumination removes risk of scope burns.
Disposable single use device helps reduce the risk of disease transmission.
Fog proof for consistent image quality.



Disposable

Designed to help reduce the risk of disease transmission
Saves time and expense of costly cleaning and sterilization
No capital expenditure to evaluate and use

Who We Are

XENOCOR is an emerging company that aims to revolutionize minimally invasive laparoscopic surgery by bringing its Xenoscope™ an innovative, single–use, HD imaging multi–purpose scope to the market. This scope promises to disrupt the high capital cost laparoscopy systems market and greatly expand the delivery of high–quality surgical care to the hundreds of millions of patients world–wide

Our Leadership

Evan Kelso

CEO

John Langell

Founder

Lane Brooks

Chief Engineer

Tony Watson

VP – Sales

Our Board

Dinesh Patel

Shawn Fojtik

Jim Hogan

Disposable HD Laparoscopes: Cost-Effective and Safe

USPTO Issues Xenocor a U.S. Patent Protecting Their Novel Offering of Surgical Scopes

Issuance of U.S. Patent No. 10,702,128 Further Bolsters Xenocor’s Intellectual Patent Portfolio Salt Lake City, UT USA June 23, 2020 -- Xenocor, Inc., a privately held company focused on identifying, developing and commercializing innovative and differentiated endoscopes to address significant unmet needs in making...

FDA Clears New Disposable Articulating 5mm Laparoscope

The FDA cleared the new Xenocor Disposable 5mm Articulating Laparoscope for minimally invasive abdominal and thoracic surgery. The Xenoscope 5mm articulating disposable laparoscope is designed to improve image quality, reduce fog, lower hospital costs, and reduce bio-hazard risk for the patient and staff.

Xenoscope™ Receives CE Mark

Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that it has received the CE Mark for the Xenoscope systems. The Xenoscope is the first...

10mm Xenoscope Press Release

Xenocor, Inc., an emerging leader in developing a new, revolutionary medical imaging platform that provides the most cost‐effective high definition laparoscopy solutions, announced today that its first product, the Xenoscope, was 510(k) cleared by the U.S. FDA for marketing and distribution. The Xenoscope is the...

“The difference in visibility is really remarkable. The Clearview Imaging Technology is really a great step forward.”

“The Xenoscope is so much lighter than the laparoscopes we were using in the past. You really notice a difference in fatigue by the end of the surgery!”

Between the better visibility, lighter construction and the polymer shaft removing the potential for arc burns, I feel that the risks of many of my procedures has been lowered significantly.



(801) 210-0385 (consultant line)



[email protected]



630 Komas Dr. Suite 200, Salt Lake City UT 84108

Reach Out

Speak With Us Today!

John Langell

Founder

John Langell, MD, PhD, MPH, MBA, FACS is a Stanford-trained minimally invasive general surgeon. He is the inventor of the concept for a new cost-effective laparoscopic platform which led to the development of the XenoscopeTM. Dr. Langell currently serves as both President and Chairman of the Board of Directors for Xenocor Inc. He is also Vice Dean for Innovation and Executive Director of the Center for Medical Innovation at the University of Utah School of Medicine. His research efforts are focused on the translation and commercialization of medical technologies and digital medical therapeutics. His work has resulted in the development of many innovative new devices and software applications in the fields of laparoscopic surgery and patient care access for advanced and resource-poor regions.

Evan Kelso

CEO

Evan Kelso brings 20 years of Clinical Sales and Marketing from both United States Surgical and Ethicon Endo-Surgery. His experience working into the laparoscopic space gives him a unique ability to to set the vision for Xenocor, obtain the best teammates for the mission and is currently working towards commercializing the Xenocor product line.

Prior to working at Xenocor, Evan started Vortex Medical a national imaging focused disposition company. He has a clinical mastery of a laparoscopy, product landscape and market fit. Clinically he is proficient in the specialties of General, Trauma, GYN, Bariatrics, CVT and Ortho/Spine.

Dinesh Patel

Board Member

Dr. Patel PhD is the founder and managing director of Patel Family Investments (2014) and co-
founded vSpring Capital ($400 million under management) in 2000 and has been a founding managing director till October 2014.

Prior to vSpring Capital, Dr. Patel was an active angel investor in over 20 biotech and technology companies. From 1985 – 1999 Dr. Patel served as Co-Founder, Chairman of The Board of Directors and President & CEO of TheraTech, Inc., a biotechnology company which he took public and eventually sold to Watson Pharmaceuticals (now Actavis) for $350 million. From 1999 to 2004 he was the Founder, Chairman, President & CEO of Ashni Naturaceuticals, Inc., a company that specializes in the research, development and marketing of clinically tested and patent-protected naturaceutical products. In 1999, Dr. Patel co-founded and was the Chairman of Salus Therapeutics, Inc., a biotechnology company focused on the research and development of nucleic acid-based therapeutics, including antisense and gene therapy drugs. He currently holds 15 US Patents and Foreign Counterparts.

Dr. Patel also served on the board of Mediconnect Global, a worldwide leader in medical record retrieval, digitization, and one of the largest cloud based health information exchange. In March 2012, Mediconnect was acquired by Verisk Analytics (VRSK) for over $377 million.

Dr. Patel serves on several non-profit boards, and has won numerous awards including; 2013 Willem J Kolff Lifetime Achievement Award, the 2011 Father of the Year, 2010 Utah Youth Village Helping Hand Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).

Dr. Patel served as co-chair of Governor Huntsman’s transition and he served as the Chairman of the USTAR Governing Authority board from 2006-2014. He is a member of the Life Sciences and Management Board at the University of Pennsylvania , on the University of Michigan’s President’s Advisory Group and on the University of Utah’s National Advisory Council.

Born and raised in Zambia, Africa, Dr. Patel received his bachelor’s degree in Pharmacy at Gujarat University located in Ahmedabad, Gujarat, India, his master’s degree from the Philadelphia College of Pharmacy and his Ph.D. in Physical Pharmacy from the University of Michigan.

Dr. Patel led the firm’s investments in Altea Therapeutics, American Academy, Athena Feminine Technologies, Axial Biotech, Coherex Medical, Exagen Diagnostics, Mirabilis Medica, Numira Biosciences, Lineagen, NanaMR, Q Therapeutics, Scintila, ZARS Pharma and Salus Therapeutics which was acquired by Genta (NASDAQ: GNTA) for $30 million.

Lane Brooks

Chief Engineer

Lane Brooks received his B.S., M.Eng., and Ph.D. degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT). He has worked as the lead engineer in camera and image sensor design in various successful startups for 15+ years. He has over 10 issued patents and over 10 publications in peer-reviewed journals. In 2013, he led the system design for the miniature microscope that was awarded the Innovation of the Year by the TheScientist.com. In 2007 he was awarded the National Defense Science and Engineering Fellowship. In 2002, he led the design for a camera awarded the distinction of World’s Thinnest Camera by Guinness World Records and Best of Show at CES. In 1999 his team won first place in the annual MIT Robot Competition.

Tony Watson

VP - Sales and Marketing

Tony Watson, BS, MBA has spent much of his 16 year medical device career commercializing medical devices, primarily with Medtronic/Covidien and more recently with TTCMed which was pre-revenue when he began leading sales and marketing efforts and took it to market. He is focused on getting the Xenocor product portfolio into the broader market to increase access to care, lower costs and simplify procedural flow.

Jim Hogan

Board Member

Jim Hogan is recently retired from Medtronic, the world’s largest medical technology company, where he was Regional President for international markets, and member of the CEO Executive Committee. Prior to his career with Medtronic, he spent 13 years with Pfizer in Sr. European leadership roles. He also founded three medical device start-ups, Biostent, Argomed and Cortrak, all of which had successful exits to major multinational companies. Jim holds undergraduate and graduate degrees from the University of Minnesota.

Troy D'Ambrosio

Board Member

Troy D’Ambrosio is currently the Executive Director of the Lassonde Entrepreneur Institute at the University of Utah, an Associate Dean of the David Eccles School of Business and holds a presidential chair. The Institute assists student and faculty from idea to launch through programs, competitions and curriculum. The Lassonde Institute is ranked #23 by the Princeton Review.

Troy D’Ambrosio is co-founder, officer and director of multiple start-up companies, which attracted over $500 million in capital; include founding Transworld Telecommunications which was sold to Sprint in 1996, Convergence Communications which was sold to Lockheed Martin in 2005and EPM Mining Ventures listed on the Toronto Venture Exchange. He has served as the VP of Investor Relations and Corporate Communication for American Stores Company, an NYSE listed company, and the Director of Mutual Fund Operations for Wasatch Advisors. He graduated from the University of Utah in 1982 and was named the Ernst & Young Entrepreneur of the Year in 2000, a v100 Technology leader in 2008 and Best in State Educational Administrator in 2009.

Shawn Fojtik

Board Member

Shawn Fojtik has 100+ combined issued and pending patents and is co-founder of Distal Access, Control Medical, CIRCA Scientific, and others with experience at GE, Boston Scientific, and Black & Decker.
His experience includes devices for cardiology, interventional radiology & oncology, electrophysiology, and other procedures.

Distal Access’s team commercialized the SPINR high-performance guidewire controller then sold it to Merit Medical in 2015. Then, Distal developed the Resectr, launched it remove uterine polyps in July 2016, and sold it to Boston Scientific in November 2016.

Control Medical’s award-winning platform is used to remove blood clots during heart attack, peripheral vascular disease, deep vein thrombosis, and stroke.

CIRCA Scientific commercialized a self-expanding rapid-sensing catheter-probe that achieved profitability in under 3 years from financing.

Shawn is an Adjunct Assistant Professor of Surgery at the University of Utah with a BS from the University of Illinois and a MA from Harvard University.